Lung Cancer FrontiersTM
"The purpose of Lung Cancer Frontiers is to acquire and disseminate new knowledge about lung cancer and how it can be most quickly and effectively diagnosed and treated."
History of Lung Cancer Frontiers
Dr. Thomas L. Petty founded Lung Cancer Frontiers in 1996, when he saw a need to stimulate interest in lung cancer among health care providers. Primarily written for pulmonologists, this newsletter is dedicated to advancing knowledge about lung cancer, with an emphasis on early diagnosis and treatment. In April 2008, National Jewish Health became the new home of Lung Cancer Frontiers. In January 2010, Dr. Jeffrey A. Kern, Professor of Medicine and Chief of the Division of Oncology at National Jewish Health, became Editor in Chief of Lung Cancer Frontiers.
Lung Cancer Frontiers Editorial Board
Contact The Editors
2013
- Breath Volatile Metabolic Biomarkers of Lung Cancer, by Peter Mazzone, MD, MPH, FCCP
- Selections from the Peer-Reviewed Literature, by Ignacio I. Wistuba, MD
2012 Issues
-
Defining the Genetic Predispostion to Lung Cancer and COPD, by James C. Willey, MD and Thomas M. Blomquist, MD, PhD
-
Selections from the Peer-Reviewed Literature, by Laurie E. Gaspar, MD
- Bronchial Carcinoid Tumors: Diagnosis and Management, by Zoran Lesic, MD and Laurie L. Carr, MD
- Selections from the Peer-Reviewed Literature, by Ali I. Musani, MD
- A Better Future for Lung Cancer Chemoprevention, by Takefumi Komiya, MD, PhD, and Phillip A. Dennis, MD, PhD
- Selections from the Peer-Reviewed Literature, by Javier J. Zulueta, MD
- Lung Cancer in Women: Differences in Epidemiology, Biology, and Therapy, by Jyoti D. Patel, MD
- Selections from the Peer-Reviewed Literature, by Heidi Roberts, MD, FRCPC
2011 Issues
- Non-Coding RNAs as Biomarkers for Lung Cancer, by Michael Ezzie, MD, Michael Chacey, MD, and Patrick Nana-Sinkam, MD
- Selections from the Peer-Reviewed Literature, by Jeffrey A. Kern, MD
- Limited Resection for Non-Small Cell Lung Cancer, by John D. Mitchell, MD
- Selections from the Peer-Reviewed Literature, by Jeffrey A. Kern, MD
- Stereotactic Body Radiation Therapy for Early Stage Lung Cancer, by Brian D. Kavanagh, MD, MPH
- Selections from the Peer-Reviewed Literature, by Steinn Jonsson, MD
2010 Issues
- Gene Therapy for Malignant Pleural Mesothelioma, by Edmund K. Moon, MD and Steven M. Albelda, MD
- Selections form the Peer-Reviewed Literature, by Laurie L. Carr, MD
- Jeffrey A. Kern, MD Named Editor in Chief of Lung Cancer Frontiers
- The Role of Immunohistochemistry in Lung Cancer, by Steve D. Groshong, MD, PhD
- Emerging Data in Lung Cancer Screening, by James L. Mulshine, MD
- In Memoriam: Thomas L. Petty, MD
- Gene Expression Profiles for the Treatment of Non-small Cell Lung Cancer: The Promise of Personalized Cancer Therapy, by John Strickler, MD and Anil Potti, MD
- Selections from the Peer-Reviewed Literature, by Patrick Nana-Sinkam, MD
2009 Issues
- Screening for Lung Cancer, by Gerard A. Silvestri, MD, MS
- Selections from the Peer-Reviewed Literature, by Richard A. Matthay, MD
- EGFR Testing in Lung Cancer is Ready for Prime Time, by Fred R. Hirsch, MD, PhD
- Selections from the Peer-Reviewed Literature, by York E. Miller, MD
- Screening for Lung Cancer, by Thomas L. Petty, MD
- Message from Michael Salem, MD, President and CEO of National Jewish Health
- Informing the Decision about Being Screened for Lung Cancer, by Claudia I. Henschke, PhD, MD, et al., for the International Early Lung Cancer Action Program Investigators
2008 Issues
- Interventional Bronchoscopy in Lung Cancer Diagnosis and Staging, Part 2, by Ali I. Musani, MD
- Selections from the Peer-Reviewed Literature, by Thomas L. Petty, MD
- Nicotine Receptors and the Risk of Lung Cancer, by Steinn Jonsson, MD, FCCP
- Interventional Bronchoscopy in Lung Cancer Diagnosis and Staging, Part 1, by Ali I. Musani, MD, FCCP
2007 Issues
Progress in Lung Cancer
by Richard A. Matthay, MD
New Genomic and Proteomic Studies in Lung Cancer Biomarker Detection
by Patrick Nana-Sinkam, MD
Two New Observational Studies Suggest Future Directions in Lung Cancer Chemoprevention
by York E. Miller, MD
Study Supports Early Screening for Lung Cancer
by Thomas L. Petty, MD
2006 Issues
7th Perspectives in Lung Cancer Conference, Athens, Greece
by Paul Baas, MD
Higher Lung Cancer Risk in Women!
by Thomas L. Petty, MD
CT: A Public Health Measure in Lung Cancer Control
by James Mulshine, MD
Lung Cancer Frontiers: 10 Year Anniversary
by Thomas L. Petty, MD
2005 Issues
New Directions for Lung Cancer Frontiers
by Thomas L. Petty, MD
Spirometry Now High Priority
by Thomas L. Petty, MD
Avastin Effective in Advanced Lung Cancer
by Thomas L. Petty, MD
Hopes for 2005: Diminishing the Dogma Drag
by Thomas L. Petty, MD
2004 Issues
Landmark Trials of Adjuvant Chemotherapy Following Complete Surgical Resection
by James R. Jett, MD
A US Preventive Services Chest Task Force Continues to Recommend Against Screening
by Thomas L. Petty, MD
Comments on Endobronchial Diagnosis and Treatment, from the 10th IASLC Conference on Lung Cancer, Vancouver, BC
by T.G. Sutedja, MD
Lung Cancer FrontiersTM is a registered trademark of National Jewish Health.
